TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00503100

Intervention type: DEVICE
Intervention: Thermal stimulation
Description: Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.

Intervention type: DEVICE
Intervention: Thermal stimulation
Description: Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.

Intervention type: DEVICE
Intervention: Thermal stimulation
Description: Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.

Intervention type: DEVICE
Intervention: Thermal stimulation
Description: Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
Study: NCT03155724

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MultiPole Pacing
Description: CRT non-responders are programmed with MultiPole pacing ON.
Study: NCT02111330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-509
Study: NCT04765787

Intervention type: DRUG
Intervention: Combination of Paracetamol 650mg + Orphenadrine 50mg
Description: In routine practice for pain , combination of Paracetamol 650 mg + Orphenadrine 50mg prescribed for 7-10 days with follow up and as per physician discretion
Study: NCT03182361

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants
Description: Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
Study: NCT04385589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin
Description: insulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: insulin
Description: insulin
Study: NCT01757444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiPAP - A40
Description: Patients receiving BiPAP AVAPS - AE ventilatory mode at home
Study: NCT02130219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure measurement
Description: The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure measurement
Description: The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure measurement
Description: The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
Study: NCT02111330

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01693549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Study: NCT01125982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
Study: NCT02169986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic reminders
Study: NCT01757444

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BiPAP - ST
Description: Patients receiving BiPAP- ST mode at home.
Study: NCT01462032

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training Executive, Attention and Motor Skills (TEAMS)
Description: Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent support and education
Description: Parents will participate in groups designed to provide information about ADHD and support for working with their child.
Study: NCT00495105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two Servings of Dairy Snacks
Description: 2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
Study: NCT01960777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Onstep

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic repair
Study: NCT02888873

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Charisma Classic
Description: The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch\&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.~Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups.
Study: NCT00659178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Description: SB-485232 (interleukin 18), pegylated liposomal doxorubicin
Study: NCT02130219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive intracranial pressure measurement
Description: The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI/CT
Description: 1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI/CT
Description: 1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume.
Study: NCT01302860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study: NCT03111511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drospirenone/Ethinylestradiol
Description: A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg orally on Days 1 and 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
Study: NCT01675245

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
Study: NCT02248181

Intervention type: DRUG
Intervention: Pramipexole
Study: NCT01775124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of 0.5 mg Ranibizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Intravitreal injections of 0.5 mg Ranibizumab
Study: NCT02130219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI/CT
Description: 1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain MRI/CT
Description: 1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.~Brain CT performed to evaluate hemorrhage and stroke volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture and cerebrospinal fluid pressure measurement
Description: Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture and cerebrospinal fluid pressure measurement
Description: Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture and cerebrospinal fluid pressure measurement
Description: Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
Study: NCT03770819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.
Study: NCT00250341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVAR
Description: 480 mcg
Study: NCT02440945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collection of blood
Description: Blood test on blotting paper DBS (for the patients recruting)
Study: NCT01757431

Intervention type: DRUG
Group type: OTHER
Intervention: Eculizumab
Study: NCT02806648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib
Study: NCT00502463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m² day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75mg/m² day 1
Study: NCT00250341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair
Description: 250/50 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Servent Diskus
Description: 50 mcg
Study: NCT03770819

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Zinc oxide gel/placebo gel will be placed into the periodontal pockets using a blunt cannula ensuring that starting from the bottom, it completely fills the periodontal pockets. The gel will be retained in the pocket for 5 minutes. The perio tip will be attached to the hand piece of the light cure unit (Wavelength: 420-480nm. Light power: 1200mw/cm2 in continuous mode) and light will be activated for 60 seconds. Following this, the pockets will be irrigated with normal saline solution (0.9%Sodium chloride).~For groups 1 and 2, sham PDT will be performed by directing the Light cure device without turning on the light beam.
Study: NCT01566370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT02868944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).
Study: NCT00502463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 750mg/m²/day day 1-5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: standard fraction up to a total dose of 70Gy/35 fractions/7weeks or accelerated regimen, up to a total dose of 72Gy/42 fractions over 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250mg/m²/week after an initial loading dose of 400mg/m²
Study: NCT00439231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
Study: NCT01466101

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Administration of placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin administration
Description: Administration of pregabalin
Study: NCT02868944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.
Study: NCT05679986

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00566826

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient support sessions
Description: Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
Study: NCT00598936

Intervention type: DEVICE
Intervention: CDI 1000 COM and INVOS 5100
Description: CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
Study: NCT01176734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tVNS-Device
Description: Active treatment with the t-VNS device.
Study: NCT00566826

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual includes standard care for TKR surgery rehabilitation.
Study: NCT04215536

Intervention type: DRUG
Intervention: Empagliflozin
Description: Empagliflozin dispensing claim is exposure

Intervention type: DRUG
Intervention: DPP-4 inhibitor
Description: DPP4 inhibitor dispensing claim is reference
Study: NCT03070080

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: restrictive fluid strategy
Description: restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conservative fluid strategy
Description: conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
Study: NCT01484210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpenhaler active - Diskus placebo
Description: randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
Study: NCT03917797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC treatment
Description: Umbilical cord-derived Mesenchymal Stromal Cell

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Methylprednisolone; Cyclophosphamide; Prednisone; Mycophenolate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: MSC infusion vehicle
Study: NCT02588326

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate drug formulation (MFF) 1
Description: Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate drug formulation (MFF) 1
Description: Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate drug formulation (MFF) 2
Description: Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone furoate drug formulation (MFF) 2
Description: Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.